LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression. In Vitro LJ001 (0.782- 200 μM; 24 h) shows no significant cytotoxicity with a CC 50 value of 146.4 μM for ST cells. LJ001 (12.5 µM; 12, 24 h) inhibits transmissible gastroenteritis virus (TGEV) and porcine deltacoronavirus (PDCoV) infection. LJ001 (12.5 µM; 1, 6,12, 24 h) decreases the TGEV and PDCoV gene mRNA expression in ST cells. LJ001 can inhibit the entry and spread of some enveloped viruses, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza, Ebola, arenaviruses and poxvi ruses. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: ST cells Concentration: 0.782, 1.563, 3.125, 6.25, 12.5, 25, 50, 100, 200 μM Incubation Time: 24 h Result: Showed slight cytotoxicity with a CC 50 value of 146.4 μM. Western Blot AnalysisCell Line: ST cells Concentration: 12.5 µM Incubation Time: 12, 24 h Result: Decreased the expression of TGEV N protein and PDCoV N-protein at 24 h and markedly reduced TCID 50 titers at 12 and 24 h. RT-PCRCell Line: ST cells Concentration: 12.5 µM Incubation Time: 1, 6, 12, 24 h Result: Inhibited TGEV and PDCoV gene mRNA expression in a time-dependent manner. In Vivo LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) shows no toxicity in mouse. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female BALB/c miceDosage: 20, 50 mg/kg Administration: Oral gavage or i.p.; daily for 7 days Result: Revealed no abnormalities except a slight elevation in serum cholesterol levels in the treated vs. vehicle control group. Form:Solid